CompletedPhase 2NCT00070304
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Peter Cole, MDRutgers Cancer Institute of New Jersey
- Intervention
- filgrastim(biological)
- Enrollment
- 33 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2004
Study locations (30)
- Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
- Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
- Children's Hospital and Health Center - San Diego, San Diego, California, United States
- UCSF Comprehensive Cancer Center, San Francisco, California, United States
- Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
- Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00070304 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →